Zahorakova Daniela, Jachymova Marie, Kemlink David, Baxova Alice, Martasek Pavel
Department of Pediatrics, First Faculty of Medicine and General University Hospital, Charles University, Prague, Czech Republic.
J Child Neurol. 2010 May;25(5):546-50. doi: 10.1177/0883073809346848. Epub 2010 Feb 5.
Rett syndrome is a neurodevelopmental disorder mainly caused by de novo mutations in the MECP2 (methyl-CpG-binding protein 2) gene. There is considerable variation in the severity of clinical features among Rett syndrome patients, even among patients with the same MECP2 mutation. In addition to X-chromosome inactivation pattern, the genetic background of the affected individual might also have a role in determining the severity of the disorder. We suggest that APOE is one of the genetic modulating factors. We analyzed clinical phenotypes of 46 patients with Rett syndrome, with confirmed MECP2 mutation. We discovered that among epsilon4 carriers, some clinical features were more severe, and the developmental regression occurred 4 months earlier on average than in those without the epsilon4 allele. Earlier onset of regression suggests a possible trend; however, it did not achieve distinctive statistical significance. Nevertheless, the epsilon4 allele of APOE may serve as a candidate modulation factor for the Rett syndrome phenotype.
瑞特综合征是一种主要由MECP2(甲基CpG结合蛋白2)基因的新生突变引起的神经发育障碍。瑞特综合征患者的临床特征严重程度存在很大差异,即使是具有相同MECP2突变的患者也是如此。除了X染色体失活模式外,受影响个体的遗传背景可能也在决定该疾病的严重程度方面发挥作用。我们认为载脂蛋白E(APOE)是遗传调节因素之一。我们分析了46例确诊为MECP2突变的瑞特综合征患者的临床表型。我们发现,在ε4携带者中,一些临床特征更为严重,与没有ε4等位基因的患者相比,发育倒退平均提前4个月出现。较早出现倒退表明可能存在一种趋势;然而,这并未达到显著的统计学意义。尽管如此,APOE的ε4等位基因可能是瑞特综合征表型的候选调节因素。